Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature. (Q31170918)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

Omar Abdel-Rahman

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Mona Fouad

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

3 July 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

141

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

295-305

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

https://scigraph.springernature.com/pub.10.1007/s00432-014-1757-5

0 references

Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1757-5

21 January 2018

Immunohistochemical expression and prognostic significance of HIF-1α and VEGF-C in neuroendocrine breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24990591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24990591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24990591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24990591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview

1 reference

https://pubmed.ncbi.nlm.nih.gov/24990591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/24990591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/24990591

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-014-1757-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990591%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31170918&oldid=1977390627"